Teleflex Incorporated To Showcase Arrow Endurance Extended Dwell Peripheral Catheter System At AVA 2015 Meeting In Dallas

Presentations Will Also Emphasize Clinician Education and Expanding Scope of Practice for Vascular Access Specialists

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading provider of medical technologies for critical care and surgery, will showcase its new Arrow Endurance^™ Extended Dwell Peripheral Catheter System at the 29th Annual Scientific Meeting of the Association for Vascular Access, in Dallas, Texas, to be held Sept. 26-29, 2015.

“Growing the Vascular Access Specialty: Expanding Your Practice to CVCs, Arterial Lines, and Beyond”

The Arrow Endurance^™ System will be discussed at a Platinum Showcase titled “The New Age of Midlines and the Arrow Endurance^™ Extended Dwell Peripheral Catheter System”, presented by Nancy Moureau, BSN, RN, CRNI, CPUI, VA-BC^™. The event will be held Monday, Sept. 28 from 4:50 p.m. to 5:50 p.m. in room Grapevine A.

Teleflex will have the extended dwell catheter system exhibited at Booth 501 in the Exhibit Hall so attendees can have hands-on experience with the device.

The Arrow Endurance^™ System is cleared by the FDA to dwell up to 29 days. The Arrow Endurance^™ System enables hospitals to avoid using multiple peripheral IVs to achieve longer dwell times while also avoiding the extra clinical risks and expenses associated with a peripherally inserted central catheter (PICC). The Arrow Endurance^™ Catheter is intended for short-term use (up to 29 days) to permit delivery of infusion therapies, pressure monitoring, high pressure injection (325 psi max.), and withdrawal of blood. To learn more about the Arrow Endurance^™ Extended Dwell Peripheral Catheter System, please visit arrowendurance.com.

Teleflex’s activities at this year’s AVA will focus on clinician education, enabling non-physician inserters to insert CVCs and arterial lines, and supporting clinicians in always selecting the right line for their patients.

“There are many vital choices that must be made so a patient gets the safest, most effective IV therapy possible. Our philosophy of “Right Line. Right Patient. Right Time.^™” helps us deliver products that align with safe patient care,” said Jay White, President of the Vascular Access Division of Teleflex. “The Arrow Endurance^™ Catheter continues to build upon this philosophy. We look forward to launching this product at this year’s AVA meeting as well as providing an additional line-up of clinical education opportunities.”

A breakfast symposium titled “Growing the Vascular Access Specialty: Expanding Your Practice to CVCs, Arterial Lines, and Beyond” will be held on Sunday, Sept. 27 from 7:00 a.m. to 8:45 a.m. in room Texas C. The presenters are clinical nurse educator Connie Girgenti, RN, VA-BC^™; Keegan Mahoney, BS, RRT, vascular access specialist in Mesa, Arizona; and Amy Bardin-Spencer. Girgenti is the co-author of the recently published article, “A Vascular Access Team’s Journey to Central Venous Catheter and Arterial Line Placement”, which appeared in the June 2015 issue of the Journal of the Association for Vascular Access.

Teleflex thought leaders are involved in several clinician education offerings at the conference. Among them is a dinner symposium, “Chlorhexidine: The Agent, the Legacy, the Novelty” with presenters Kamna Giare-Patel, MS, RN and Amy Bardin-Spencer, MS, RRT, VA-BC^™. Patel is Director, Research and Development at Teleflex, and she has done extensive work in developing chlorhexidine protected catheters. Bardin-Spencer is a Senior Clinical Marketing Specialist for the company. The symposium will be held Sunday, Sept. 27 from 6:15 p.m. to 8:15 p.m. in room Texas C.

Teleflex will also have clinical education activities at its booth, where phantoms and models will be used to demonstrate the full range of the company’s vascular access devices. The company is also offering its popular Vascular Access Procedural Cadaver Lab at the meeting site.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow^®, Deknatel^®, Hudson RCI^®, LMA^®, Pilling^®, Rusch^® and Weck^® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

VA-BC is a trademark of The Vascular Access Certification Corporation.
Teleflex, the Teleflex logo, Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rusch, Weck, and Arrow Endurance are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.
© 2015 Teleflex Incorporated. All rights reserved. MC-001436

Help employers find you! Check out all the jobs and post your resume.